Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.70% is 52% below its 1-year average of 7.67%, near the low end of its 1-year range (3.04%–21.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 50.10% below its 12-month average of 7.41%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.70%.
DEBT TO ASSETS RATIO
3.70%
DEBT TO ASSETS RATIO AVG TTM
7.41%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-50.10%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 599 covered companies
CURRENT VS SECTOR MEDIAN
+3599.71%
vs the sector median at left
Market Cap
$322.30M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$333.78M
Debt to Assets Ratio
0.74%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$308.22M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$341.18M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$302.30M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $323.01M | 3.70% | 7.41% | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $322.30M | 0.16% | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $322.03M | 0.10% | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $333.78M | 0.74% | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $334.39M | 0.24% | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.22M | 0.04% | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.18M | 0.03% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $302.30M | 0.00% | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $348.84M | 0.38% | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $295.59M | 0.04% | N/A | N/A | N/A |
Debt/Assets
3.7%
Debt/Equity
0.05
Current Ratio
3.35
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.70% |
| 2026-03-31 | 3.04% |
| 2025-12-31 | 4.88% |
| 2025-09-30 | 3.81% |
| 2025-06-30 | 21.64% |
| 2025-03-31 | 9.26% |
| 2024-12-31 | 7.37% |
